Hint mode is switched on Switch off

Neurocrine Biosciences, ordinary share
NBIX, US64125C1099

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Neurocrine Biosciences, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in
API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States.
  • Issuer
  • Full borrower / issuer name
    Neurocrine Biosciences, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Related Stock indices

Indicators

News

01/08/2026 Neurocrine Biosciences (NASDAQ: NBIX) Shows Strong Financials and Strategic Growth
14/05/2026 Neurocrine Biosciences: Of The Original Report To Include The Audited Consolidated Financial Statements Of Soleno (as Defined In The Original Report) As Of And For The Year Ended December31, 2025 And To Include The Unaudited Interim Condensed Consolidated Financial Statements Of Soleno As Of And For The Three Months Ended March 31, 2026; And (ii)update The Information In Item 9.01(b) Of The Original Report To Include The Unaudited Pro Forma Condensed Combined Financial Information Of The Company, Consisting Of The Unaudited Pro Forma Condensed Combined Statements Of Income For The Six Months Ended June30, 2026 And The Year Ended December31, 2025. This Amendment No.1 Does Not Amend Any Other Item Of The Original Report Or Purport To Provide An Update Or A Discussion Of Any Developments At The Company Subsequent To The Filing Date Of The Original Report
14/05/2026 Neurocrine Biosciences: Entry Into A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An, Regulation Fd Disclosure, Financial Statements And Exhibits
06/05/2026 Neurocrine Biosciences (NASDAQ: NBIX) Drives Growth with Strong Financials and Strategic Pipeline Expansion
05/04/2026 Neurocrine Biosciences: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.